Proxy
Aurora Biosciences Corp.
Aurora Biosciences Corp. designs, develops and sells proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines by the pharmaceutical and biopharmaceutical industries.
Value
Total number of shares outstanding as of Dec. 21, 1999 17,300,000
Price of each share of common stock as of Dec. 21, 1999 $16.625
Aggregate market value as of Dec. 21, 1999 $287,612,500
Performance Record
For year ended Dec. 31, in thousands, except per-share data
1998 1997 1996
Revenues $26,538 $14,908 $2,217
Net income (loss) $(18,653) $267 $(2,933)
Net income (loss) per share $(1.14) $0.02 $(3.86)
Total assets $50,955 $63,036 $17,515
Directors
Timothy J. Rink, 52, served as chairman, president and CEO since January 1996. He is also a director of CoCensys, Inc., a biopharmaceutical company.
James C. Blair, 59, has been director since March 1996. He has been a managing member of Domain Associates, LLC, a venture capital firm, since 1985. He is also a director of Amylin Pharmaceuticals, Inc., Trega Biosciences, Inc. and Vista Medical Technologies, Inc.
Kevin J. Kinsella, 53, has been a founder and director since its inception in May 1995. He is the chairman, CEO and president of ANCILE Pharmaceuticals, Inc.
Hugh Y. Rienhoff Jr., 46, has been director since March 1996. He has been the CEO of Kiva Genetics, Inc., since September 1998. He is also a director of Microcide Pharmaceuticals, Inc.
Lubert Stryer, 61, has been a director since March 1996 and serves as a scientific advisor. He is a Winzer professor in the School of Medicine and professor of neurobiology at Stanford University. He is also a director of Affymetrix, Inc.
Roy A. Whitfield, 45, has been a director since September 1997. Since June 1993, he has been CEO of Incyte Pharmaceuticals, Inc.
Timothy J. Wollaeger, 55, has been a director since March 1996. Since 1993, he has been a general partner of Kingsbury Associates; Kingsbury Capital Partners, LP; Kingsbury Capital Partners, LP II; and Kingsbury Capital Partners, LP III, all venture capital investment firms.
Executive Compensation
Officers Cash Compensation
Timothy Rink, president, CEO and chairman $425,012
Paul Grayson, senior vice president of corporate development $231,667
Harry Stylli, senior vice president of screen technology and new
technology ventures $214,417
Paul England, senior vice president of research $191,686
John Mendlein, vice president of intellectual property and senior legal counsel $203,333
Significant Stock Ownership
Number of shares Percent
March 8, 1999
The Kaufmann Fund, Inc. 3,002,000 17.6
BB Biotech and affiliates 1,421,500 8.3
Directors and officers as a group 1,761,513 10.2
Other Information
Headquarters: 11010 Torreyana Road, San Diego CA 92121; (858) 404-6600; (858) 404-6714; (www.aurorabio.com)
Auditors: Ernst & Young LLP, San Diego
Information was compiled from the company’s annual and proxy reports.
